Medidata Solutions, Inc. (NASDAQ:MDSO) EVP Michael Pray sold 5,944 shares of the stock in a transaction on Friday, November 17th. The stock was sold at an average price of $70.47, for a total transaction of $418,873.68. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of Medidata Solutions, Inc. (NASDAQ MDSO) traded up $0.43 during midday trading on Monday, hitting $69.07. 286,605 shares of the stock were exchanged, compared to its average volume of 547,822. The firm has a market capitalization of $4,010.00, a PE ratio of 82.70, a price-to-earnings-growth ratio of 4.43 and a beta of 1.77. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.29 and a quick ratio of 3.37. Medidata Solutions, Inc. has a 1-year low of $47.77 and a 1-year high of $85.92.
Medidata Solutions (NASDAQ:MDSO) last issued its earnings results on Thursday, October 26th. The company reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. The business had revenue of $140.08 million during the quarter, compared to analysts’ expectations of $141.27 million. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.28 earnings per share. equities research analysts expect that Medidata Solutions, Inc. will post 0.77 earnings per share for the current fiscal year.
Several equities analysts have issued reports on MDSO shares. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $92.00 price objective on shares of Medidata Solutions in a report on Friday, October 27th. Citigroup Inc. reaffirmed a “buy” rating and set a $95.00 price objective (up from $94.00) on shares of Medidata Solutions in a report on Monday, July 24th. KeyCorp reaffirmed a “buy” rating and set a $86.00 price objective on shares of Medidata Solutions in a report on Sunday, September 17th. Dougherty & Co raised shares of Medidata Solutions from a “neutral” rating to a “buy” rating and set a $75.00 price objective on the stock in a report on Monday, November 13th. Finally, Zacks Investment Research raised shares of Medidata Solutions from a “sell” rating to a “hold” rating in a report on Friday, November 10th. Five analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $83.54.
Several hedge funds and other institutional investors have recently modified their holdings of the company. California Public Employees Retirement System raised its position in shares of Medidata Solutions by 1.2% in the third quarter. California Public Employees Retirement System now owns 104,076 shares of the company’s stock valued at $8,124,000 after buying an additional 1,276 shares during the last quarter. Zions Bancorporation acquired a new stake in shares of Medidata Solutions in the third quarter valued at about $256,000. Jane Street Group LLC raised its position in shares of Medidata Solutions by 112.8% in the third quarter. Jane Street Group LLC now owns 9,505 shares of the company’s stock valued at $742,000 after buying an additional 5,038 shares during the last quarter. AMP Capital Investors Ltd acquired a new stake in shares of Medidata Solutions in the third quarter valued at about $2,194,000. Finally, Polen Capital Management LLC acquired a new stake in shares of Medidata Solutions in the third quarter valued at about $205,000. Institutional investors and hedge funds own 97.52% of the company’s stock.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.